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Kinetics and mechanism of amyloid formation by the prion 
protein Hl peptide as determined by time-dependent ESR 
Karen M Lundberg’, Chris J Stenlandl, Fred E Cohen2, Stanley B Prusiner3 
and Glenn L Millhauserl 
Background: Peptides derived from three of four putative a-helical regions of 
the prion protein (PrP) form amyloid in solution. These peptides serve as models 
for amyloidogenesis and for understanding the (Y helix-+ f3 strand conformational 
change that is responsible for the development of disease. Kinetic studies of 
amyloid formation usually rely on the detection of fibrils. No study has yet 
explored the rate of monomer peptide uptake or the presence of nonfibrillar 
intermediate species. We present a new electron spin resonance (ESR) method 
for probing the kinetics of amyloid formation. A spin label was covalently attached 
to a highly amyloidogenic peptide and kinetic trials were monitored by ESR. 
Results: Electron microscopy shows that the spin-labeled peptide forms 
amyloid, and ESR reveals the kinetic decay of free peptide monomer during 
amyloid formation. The combination of electron microscopy and ESR suggests 
that there are three kinetically relevant species: monomer peptide, amyloid and 
amorphous aggregate (peptide aggregates devoid of fibrils or other structures 
with long-range order). A rather surprising result is that amyloid formation 
requires the presence of this amorphous aggregate. This is particularly 
interesting because PrPs’:, the form of PrP associated with scrapie, is often 
found as an aggregate and amyloid formation is not a necessary component of 
prion replication or pathogenesis. 
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Conclusions: Kinetic analysis of the time-dependent data suggests a model 
whereby the amorphous aggregate has a previously unsuspected dual role: it 
releases monomer into solution and also provides initiation sites for fibril 
growth. These findings suggest that the B-sheet-rich PrPSC may be stabilized 
by aggregation. 
Introduction 
Prion diseases include scrapie (in sheep), bovine spongio- 
form encephalopathy (mad cow disease), and the human 
diseases fatal familial insomnia, Creutzfeldt-Jakob disease, 
Gerstmann-Str+rssler-Scheinker disease and kuru [ 141. 
The scrapie isoform of the prion protein (PrPsc) is so named 
because it appears to be the sole macromolecule that is 
responsible for transmission of prion diseases. The normal 
cellular PrP isoform (PrPC) is produced primarily in healthy 
tissue of the central nervous system. In prion diseases, PrPSC 
accumulates. This isoform has the same primary structure 
as PrPC but a different tertiary structure. The conversion of 
PrP” into PrPsc involves a binding event between existing 
PrPsc and PrPC [2,5] and recent studies show that PrPSc 
functions as a template for this structural transition [6]. 
Circular dichroism and Fourier transform infrared spec- 
troscopy have been used to investigate the secondary 
structure of PrPC: and PrPSC [7-91. Both species have been 
isolated under non-denaturing conditions. The cellular 
form was found to contain 42% (Y helix and 3% l3 sheet [S]; 
in contrast, PrPSC has an o-helix content of 30% and a 
B-sheet content of 43%. Spectroscopic studies on PrP- 
derived peptides support these findings [lO,ll]. Thus, a 
protein refolding transition involving c1 helix-B sheet is 
implicated in the interconversion of PrPC to PrPSc. 
F.E.C., S.B.P. and coworkers [12] proposed a model in 
which PrPC possesses four c-Y-helical regions. Nuclear mag- 
netic resonance (NMR) studies of PrP(90-145) supports 
the existence of the first of these a-helical regions [lo] and 
an NMR structure of PrP(lZl-231) documents the exis- 
tence of the third and fourth o-helical regions [13]. Of the 
13 disease-causing point mutations, 1’2 are found in or near 
the regions of secondary structure. Peptides derived from 
three of the experimentally documented (Y helices have 
been shown to form amyloid that exhibits the same bi- 
refringence and electron microscopy features as observed 
in some prion diseases, Alzheimer’s disease and the other 
amyloidoses [14]. The peptide sequence AGAAAAGA, 
corresponding to residues 113-120 from Syrian hamster 
PrP, a part of the Hl region, is of particular interest. This 
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sequence is the most amyloidogenic fragment derived 
from PrP and is conserved in all known PrP sequences 
[15]. Also, the Alall7+Val mutation that segregates with 
Gerstmann-Straussler-Scheinker disease is found within 
this sequence [16]. A molecular model, which takes into 
account both the spectroscopic observations and the sites 
of disease-associated mutations, suggests that this 
sequence forms part of a B sheet in PrPsc [ 171. 
Although the formation of amyloid is not a necessary conse- 
quence of prion disease, multimerization of monomeric 
units is thought to be an essential component of PrPsC repli- 
cation. Thus, it is important to understand how conforma- 
tionally plastic regions of PrP can associate to form ordered 
aggregates. Fibrils that are characteristic of amyloid are 
composed largely of B sheet [ 181. Hence, amyloid formation 
may provide an insight into the rate at which PrP-derived 
peptides rearrange into extended B-sheet conformations. In 
addition, PrPsC can, upon proteolytic cleavage near residue 
90 and addition of detergent, form prion rods which have 
been shown to be amyloid on the basis of ultrastructural 
and tinctorial criteria [19,20]. Finally, short fibril-forming 
peptides can serve as useful models for amyloidogenesis, 
which is central to diseases such as Alzheimer’s [Zl]. 
It is widely recognized that in z&-o kinetic studies provide 
an insight into the mechanism responsible for the forma- 
tion of amyloid. To date, most kinetics measurements 
have relied upon the time-dependent detection of 
extended fibrils. For example, Come et al. [ZZ] used solu- 
tion turbidity as a means of assessing fibril concentration 
in samples containing PrP-derived peptides. They 
demonstrated a kinetic lag time similar to that observed in 
crystal growth. Lomakin et al. [23] recently investigated 
the growth of B-amyloid peptide fibrils by quasielastic 
light scattering. The authors proposed a kinetic model in 
which peptide micelles rearrange to form a nascent fibril 
that subsequently elongates upon the attachment of 
peptide from solution. Although such experiments are 
essential, they cannot reveal complete descriptions of the 
kinetic processes responsible for the development of 
amyloid. Detailed kinetic studies require the identifica- 
tion of all the species present in solution. Experiments 
that detect only fibril concentration and/or growth cannot 
address important issues such as the rate law associated 
with the uptake of the monomeric peptide or the presence 
of intermediate species such as dimers or trimers. Such 
information would be vital for determining which of the 
proposed prion replication mechanisms actually occurs. 
To address these issues, we present electron spin 
resonance (ESR) and electron microscopy (EM) experi- 
ments on a spin-labeled analog of the PrP(113-120) 
sequence AGAAAAGA. The peptide AGAACAGA 
[denoted PrP( 113-120)-S] was synthesized and a nitroxide 
spin label was covalently attached to the cysteine residue. 
The resulting spin-labeled analog [PrP( 113-120)-SSL] 
forms amyloid that is similar to that of the parent sequence. 
The spin-label reporter group is detectable by ESR down to 
micromolar concentrations. Monomeric peptide and aggre- 
gated species give distinct ESR signals, allowing each to be 
followed independently during amyloid formation. EhI is 
used to assess the development of fibrils. By combining 
ESR and EM, three species are identified: monomeric 
peptide; amorphous aggregate that does not contain 
amyloid; and amyloid. We find no evidence for the pres- 
ence of low molecular weight multimeric species such as 
dimers or trimers. ESR is also used in combination with a 
filtering experiment to explore kinetic reversibility. A 
three-state kinetic model that is consistent with the experi- 
mental results is proposed. A key feature of this model is 
the previously unsuspected dual role of the amorphous 
aggregate. This species releases peptide into solution and 
also provides sites for the initiation of amyloid growth. 
Results 
Spin-labeled peptides form amyloid 
Amyloid formed readily from buffered solutions of 
PrP(113-120), PrP(113-120)-S and PrP(113-120)-5SL 
after 2-3 days, as determined by transmission EM. The 
fibrils were at least 3 pm long and -6-8 nm wide for each 
sample, as shown in Figure 1. Fibrils from the parent 
PrP(113-120) peptide had periodic twists whereas fibrils 
from the unlabeled and labeled analogs were straight. All 
fibrils were unbranched. The spin-labeled fibrils were 
stained with Congo Red (Sigma) and exhibited the 
green-gold birefringence that is characteristic of amyloid. 
Thus, PrP( 113-lZO)-5SL retains the fibril-forming charac- 
teristics of the parent PrP( 113-120) peptide. 
ESR spectra exhibit time-dependent characteristics 
To initiate each ESR-detected kinetic trial, measured 
amounts of PrP(113-120)-5SL were mixed with buffer 
and agitated to aid dissolution. ESR measurements were 
commenced within Smin. Figure 2a shows two ESR 
spectra of PrP( 113-120)-SSL taken from a single sample at 
Smin and 2 h after dissolution. The sharp three-line first- 
derivative spectrum is characteristic for a rapidly tumbling, 
monomeric nitroxide-labeled peptide in solution. The 
rotational correlation time TV for this peptide, as deter- 
mined from the spectra is 0.15ns which is the expected 
value for a monomeric peptide possessing the molecular 
weight of PrP( 113-120)-5SL at 298K [24]. The center line 
is expanded to show clearly the loss of amplitude for the 
2 h spectrum. Comparison of the two spectra shows that, as 
time progresses, the concentration of free peptide decays. 
Figure 2b shows the same data as Figure Za, but with the 
spectra displayed in the ESR absorption mode. In this 
representation, a broad spectral component can be seen, 
underlying the sharp three-line nitroxide spectrum. Pass- 
ing PrP( 113-120)-5SL solutions through a 0.22 km filter 
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Figure 1 Figure 2 
Electron micrographs of the peptides (a) AGAAAAGA 
[PrP(113-120)1, (b) AGAACAGA [PrP(ll3-120)-51 and (c) 
spin-labeled AGAACAGA [PrP(113-120)-5SLI. All three peptides 
form fibrils. 
completely removes this broad signal, indicating that this 
spectral feature arises from a high molecular weight peptide 
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ESR spectra of PrP(1 13-l 20)-5SL in solution at the beginning of a 
kinetic trial (solid line) and after 2 h (dashed line). (a) The conventional 
first-derivative ESR display with the center line expanded to show the 
loss of signal intensity after 2 h. (b) The integrated signal showing the 
absorption spectrum. The broad background associated with 
aggregate is apparent under the sharp three-line spectrum. 
aggregate. Support for this interpretation comes from the 
shape of the broad spectrum. In solid and solid-like materi- 
als containing nitroxides, electron spin-spin exchange inter- 
actions influence the shape of the ESR spectrum. If the 
concentration is high, such as for polycrystalline nitroxide 
solids or highly concentrated solutions, the spin-spin inter- 
action leads to exchange narrowing and an ESR spectrum 
containing a single Lorentzian shaped line [25,26]. The 
broad spectral component from the PrP( 113-120)-5SL 
aggregate fits well to a Lorentzian function and the width at 
half height is -33Gauss, which is similar to that observed 
for unordered tempone microcrystals. 
The concentrations of peptide in the aggregate and 
monomeric forms were determined at the beginning of 
each kinetic trial. Figure 3 shows how the concentrations of 
these two species depend upon total initial peptide 
concentration. The solid lines are linear least-squares fits 
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Figure 3 
6ooL 
Concentration of total peptide (FM) 
Concentrations of the PrP(ll3-120)-5SL peptide in the monomeric 
form (squares) and as aggregate (circles) plotted against total peptide 
concentration as determined at the beginning of each trial. 
to the data. The initial aggregate concentration correlates 
linearly to total peptide concentration. The x intercept 
(zero aggregate concentration) is 51535 FM. Thus, when 
the total peptide present is less than -5O$U, all of the 
peptide will exist as monomer that is free in solution. 
Figure 3 shows that the resultant monomer concentration 
varies from 23 FM to 143 p,M and shows little correlation to 
total peptide concentration. 
Kinetic experiments were performed by recording spectra 
as a function of time. The time-dependent monomer con- 
centration was followed using the peak-to-peak amplitude 
of the first derivative centerline where the aggregate deriv- 
ative signal makes a negligible contribution to the ampli- 
tude of the derivative spectrum. We examined 32 samples 
of various total peptide concentration. Half of the samples 
(16/32) showed no change in the monomer signal during 
the initial 3 h, regardless of total peptide concentration 
(which ranged from approximately 10pM to 175 PM). A 
common feature of these samples is that none of them con- 
tained ESR-detectable aggregate. Of the 16 samples that 
did exhibit a change in monomer concentration during the 
initial 3 h, all contained aggregate. The first 3 h of these 16 
kinetic trials are shown in Figure 4. Each trial reveals an 
initial decay within the first OS-l.Oh followed by a more 
gradual decay that continues for two weeks (see below). 
As the ESR signal that is associated with free 
PrP(113-120)-5&L decays, the aggregate signal corre- 
spondingly grows, as shown for one trial in Figure Sa. 
Quantitative absorption signal integration demonstrates 
that the sum of the free PrP(113-120)-SSL concentration 
and the aggregate concentration is approximately constant 
during the kinetic trials to within experimental error. Thus, 
Figure 4 
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The first 3 h of the 16 kinetic trials observed for PrP(1 13-l 20)-5SL. 
Trials starting with (a) monomer less than 50 )*M and (b) monomer 
greater than 50 FM are separated for clarity. Each trial exhibits an initial 
exponential decay within the first hour. There is no evidence of a lag 
period. Solid lines are fits to equation 1. 
the ESR signal represents all the peptide present in solu- 
tion. The disappearance of the monomer is not due to set- 
tling.or destruction of the spin label but, instead, is caused 
by conversion of the free peptide to a solid-like form. 
ESR may also be used to determine whether the peptide is 
oligomerizing in solution. The width of the narrow line that 
is associated with the free peptide is approximately propor- 
tional to the peptide rotational correlation time [24,27]. 
Thus, monodisperse peptide dimers or trimers, for 
example, would give spectral lines that are two or three 
times broader, respectively, than those for the monomer. A 
convenient way to determine if there is significant 
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Figure 5 
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Time-dependent characteristics of the ESR signal. (a) The time- 
dependent changes in concentration of the monomer (circles) and the 
aggregate (squares), showing that as the monomer concentration 
decreases the aggregate concentration increases. The line is fitted to 
the monomer signal and then reflected about they= 0 line to show 
that it approximately describes the growth of the aggregate 
concentration. To within experimental error, loss of monomer is 
compensated by growth of aggregate. (b) The time-dependent line 
width of the monomer signal. To within experimental error, the width is 
constant indicating that ESR does not detect dimers, trimers or other 
low molecular weight oligomers. 
Figure 6 
Electron micrographs of PrP(1 13-120)-5SL obtained (a) immediately 
after dissolution and (b) after 1 h. The micrograph in (a) shows only 
unstructured aggregates of peptide. Fibrils were not found in any 
samples that were dried down immediately after dissolution. In 
contrast, (b) shows the emergence of fibrillar structures. 
oligomerization is to examine the line width of the central 
peak as a function of time, as shown in Figure Sb. There is 
no line width variation, to within experimental error, indi- 
cating that the only ESR-detectable species in solution is 
the peptide monomer. But the existence of small popula- 
tions (~5%) of higher oligomers in a solution of mainly 
monomers cannot be ruled out. 
EM detects two aggregate species: amorphous aggregate 
and amyloid 
EM was employed to determine the nature of the aggre- 
gated species. Samples were prepared using the same meth- 
ods used for the ESR experiments. At various times after 
dissolution, samples were dried on EM grids and stained as 
described above. Distinct time-dependent morphological 
stages were observed (Figure 6). Micrographs taken at 
time = zero reveal a rough surface that apparently contains 
amorphous aggregates of peptide. These aggregates do not 
contain the regular extended fibrillar structure associated 
with amyloid. At least five different samples were carefully 
examined and none of them contained evidence for fibrillar 
structures. As a control, a soluble spin-labeled peptide 
[ZS] with the following sequence- Ac-AAAAKAACA- 
KAAAAKA-NH2 3K-8 -was dried on a grid and treated to 
the same staining procedure used for the PrP peptides. 
Careful examination by EM did not reveal the amorphous 
aggregate (as seen in Figure 6) or amyloid (Figure 1). 
At 1.0-2.5 h after dissolution, EM of PrP(113-120)-SSL 
revealed short fibril-like structures along with the amor- 
phous aggregate. Typically, fibrils appeared to be connected 
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Figure 7 
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Kinetic trials of eight samples followed for up to 15 days plotted 
semilogarithmically. The solid lines, which are fits to equation 1, reveal 
the double exponential behavior of the monomer uptake. 
to the amorphous aggregate and no short fibrils were found 
in regions that lacked amorphous aggregate. Finally, after 
several hours in solution, there were collections of full-sized 
librils (Figure 1). In samples that had been filtered to 
remove aggregate, no amorphous aggregate or librils were 
observed by EM after 18 h in solution. 
Characterizing the kinetics of amyloid formation 
ESR distinguishes peptide that is free in solution from 
aggregate. Furthermore, the ESR spectra suggest that, 
within the detection limit of ESR, the only nonaggregated 
solution species is monomeric PrP( 113-120)-5SL peptide. 
Complementary EM experiments reveal two distinct 
aggregate species: amorphous aggregate and amyloid. 
Combining the two techniques allows us to probe the 
interconversion among these three distinct species. At the 
outset, amorphous aggregate and free peptide are present. 
These two species decline, and librils are observed; Iilter- 
ing experiments suggest that fibril growth requires the 
presence of amorphous aggregate. 
Of the 16 kinetic trials that showed a decrease in the 
monomer concentration, eight trials were allowed to 
proceed with periodic monitoring for up to 15 days (shown 
as a semilog plot in Figure 7). After the initial decay 
(Figure 4), the monomer peptide signal continued to decay 
although at a much slower rate. The position of the sample 
in the ESR cavity was varied to determine whether the slow 
decay was a consequence of peptide amorphous aggregate 
and/or amyloid settling in the sample tube. The concentra- 
tion of total aggregate (amorphous aggregate and amyloid) 
was constant throughout the ESR sample, indicating that 
settling was not responsible for the observed slow decay 
and that, in contrast, the solution peptide continued to 
convert to an aggregate species. 
ESR first derivative peak-to-peak heights (Figures 4,7) 
were fitted to the double exponential function: 
[monomer] 
t =ae (1) 
where A, describes the initial decay and h, describes the 
slow decay. The fits are shown as solid lines in Figures 4 
and 7. While there is some scatter, in general equation 1 
provides a good fit for most of the experimental data. A, 
ranges from 1.1 h-r to 8.8 h-l (corresponding to time con- 
stants A,-’ from 0.9 h to 0.1 h) and X2 ranges from 0.007 h-l 
to 0.025 h-’ (143 h to 40 h). 
To elucidate the features of a kinetic model, it is impor- 
tant to determine how the various fitting parameters ((u, Xi, 
etc.) depend upon peptide and aggregate concentration. 
This is typically achieved in conventional homogeneous 
kinetics studies by varying the concentration of a single 
chemical species while holding constant the concentra- 
tions of all other species. Because we are examining a het- 
erogeneous material that only partially dissolves, however, 
it is difficult to exert detailed control over how the total 
peptide partitions between amorphous aggregate and free 
solution peptide. To address this difficulty we used multi- 
ple linear regression [29,30]. Each parameter in equation 1 
was simultaneously regressed against the initial concentra- 
tions of amorphous aggregate and monomer peptide. To 
within experimental error, (Y, B, y and X, showed no sys- 
tematic variation with respect to the concentrations of 
amorphous aggregate or monomer peptide. But the A, 
parameter did reveal a dependence on the amorphous 
aggregate concentration (Figure 8). The slope and inter- 
cept are (7.9+2.3)x10-3 h-l p&I* and 1.7f0.68h-I, respec- 
tively. There is a high level of scatter as indicated by an RZ 
statistic of 0.47, so this correlation is tentative. 
Figures 2, 4 and 7 clearly show that the concentration of 
monomer peptide decreases monotonically through each 
kinetic trial. To elucidate further the kinetic process 
leading to fibril formation, it is important to know whether 
amorphous aggregate and/or fibril can release monomer 
back to solution. A kinetic trial was initiated and allowed 
to run for six days. The resulting sample was filtered 
(0.22 pm) to separate amorphous aggregate and fibril from 
monomeric peptide. The solid was redissolved and the 
concentration monitored by ESR. The result is shown in 
Figure 9. The data show an increase in monomer concen- 
tration indicating the release of free monomer from the 
solid species. Equation 1 was fitted to the data (solid line) 
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Figure 8 Figure 9 
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Correlation of A, (equation 1) to aggregate concentration. The line 
represents the linear fit with slope and intercept: 
(7.9 + 2.3) x 103 h-t JLM-I and 1.7 f 0.68 h-l, respectively. 
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Release of monomer from redissolved filtered aggregate. The value of 
A, obtained from the fit (solid line) is comparable to values obtained 
from the experiments shown in Figure 4. 
and the resulting value for A, was within the range of 
values obtained from the experiments shown in Figure 4. 
Summary of experimental results and proposal of a kinetic 
model for the early kinetic phase 
The data presented here, indicate that the spin-labeled 
PrP( 113-120)-S sequence forms amyloid that is similar to 
the parent peptide sequence. ESR detects two distinct 
signals: one associated with monomer PrP(113-lZO)-5SL 
and the other with aggregate. EM suggests that the aggre- 
gate is composed of amyloid and an unstructured amor- 
phous aggregate. Inspection of micrographs obtained 
within the first 2 h shows that fibrils are found near amor- 
phous aggregate. Parallel ESR and EM experiments 
suggest that only amorphous aggregate and monomer are 
present at the outset of each kinetic trial. In addition, Cl- 
tering the amorphous aggregate eliminates both the ESR- 
detected kinetic decay observed for the monomer and 
EM-detected formation of fibril. In kinetic trials, the 
monomer peptide concentration decays for two weeks 
(when kinetic trials were typically terminated) and the 
resulting time-dependence follows a double exponential 
function (equation 1). The observed rate for the initial 
decay is -3-S h-l and depends on the concentration of 
amorphous aggregate. EM reveals that short fibrils form 
within the same time period. Samples filtered to remove 
the monomer reveal that monomer is released back to 
solution from amorphous aggregate and/or fibril. 
The kinetic data suggest that amorphous aggregate is 
required for the formation of fibril. Monomer in the pres- 
ence of amorphous aggregate begins to decay within the 
dead time of each kinetic trial (-5min). The uptake of 
monomer is concomitant with fibril formation and the 
observed rate is proportional to the concentration of amor- 
phous aggregate. Taken together, these observations 
suggest that fibril growth is initiated by amorphous aggre- 
gate and, perhaps, takes place on the surface of amorphous 
aggregate particles. To model these observations, a three- 
state kinetic scheme is presented in Figure 10. Amor- 
phous aggregate is considered to be a disordered solid that 
provides a source of monomer peptide [31]. Monomer may 
only be released from sites on the amorphous aggregate 
surface. In turn, a certain fraction of the surface peptides 
on the amorphous aggregate possess the proper conforma- 
tion to initiate fibril growth. Monomer peptide attaches to 
these specific sites leading to libril elongation. 
Release of monomer from the amorphous aggregate is 
characterized by the zeroth order rate constant kAm, 
where k, is the rate constant of monomer release per site 
and rnr\ is the number of sites in the sample [32]. Simi- 
larly, k,m, characterizes the attachment rate of monomer 
to the mF fibril ends in the sample. This second process is 
first order with respect to the concentration of monomer in 
the solution. Representing monomer by the symbol M, 
the rate law for M is given by: 
z = khmA - kFmF h1 (2) 
The solution to equation 2 is: 
ibl, = M,, + (Ril, - M,,)e-k~mF ’ (3) 
where M, is the initial concentration of monomer and M,, 
is the steady state concentration of monomer given by 
kAmA/kFmF. 
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Amorphous Km Km Flbril 
aggregate > Monomer __3 Amorphous 
aggregate 
A model proposed to explain the early kinetic decay of monomer. 
Amorphous aggregate, which is formed at high concentration of total 
peptide (> 50 PM), serves as a storage pool releasing monomer to 
solution. The surface of amorphous aggregate also provides specific 
fibril initiation sites. Fibril growth sequesters monomer from solution. 
The kinetic behavior of this model is given by equation 3. 
Equation 3 captures many of the features observed for the 
decay of monomer within the first several hours of each 
kinetic trial. The observed rate A, in equation 1 is equiva- 
lent to the model value kFml;. At the outset there is a con- 
centration of monomer that exceeds M,,. This excess decays 
exponentially according to the rate constant k,m,. After this 
initial decay, the release of monomer by amorphous aggre- 
gate is balanced by the uptake of monomer as the fibrils 
elongate and the monomer concentration achieves a steady 
state. Because fibril formation takes place on the surface of 
amorphous aggregate, mF should depend on the amorphous 
aggregate concentration. Thus, the initial decay should vary 
in proportion to the concentration of amorphous aggregate 
which is experimentally observed (Figure 8). 
The proposed kinetic model does not account for the slow 
decay of monomer that continues after the first several 
hours. It is most likely that the slow decay results from the 
eventual loss of amorphous aggregate as monomer is 
released. This loss may be included using the ad hoc 
expression: 
(4) 
where rni\ ,, is the number of sites releasing monomer at t = 0 
and k, represents the rate constant for the loss of such sites 
as the concentration of amorphous aggregate decreases. 
Incorporating equation 4 into equation 2 and solving gives a 
double exponendal decay (without an additive constant) for 
the decay of monomer. 
It should be noted that the kinetic data presented here 
could be readily fitted to other kinetic models. For 
instance, one could propose reversible reactions between 
amorphous aggregate and solution monomer and between 
monomer and fibril. Alternatively, there could be direct 
reaction from amorphous aggregate to fibril arising from 
rearrangement of peptides on the surface of the aggregate. 
It is our view that the model offered above provides a 
good working hypothesis and is presently the simplest 
scheme consistent with the experimental observables. 
Discussion 
The experiments presented here demonstrate that a spin- 
labeled analog of the PrP(113-120) sequence retains the 
tendency to form amyloid. The kinetic uptake of the 
PrP(113-120)-5SL peptide is readily observed by ESR and 
En1 detects the concomitant formation of amyloid. In addi- 
tion to monomer and amyloid, these experiments suggest 
that amorphous aggregate plays a key role in amyloidogene- 
sis. Amorphous aggregate has been recognized in previous 
works as a kinetically favored, but thermodynamically unfa- 
vored intermediate that is involved in the crystallization of 
globular proteins [31,33]. The conventional role for amor- 
phous aggregate in cr)rstallization is essentially that of a 
storage pool of polypeptide, but the work presented here 
suggests that an amorphous aggregate can have a distinct 
and obligatory role in amyloid formation. The lack of a lag 
time for monomer uptake, the correlation of A, to the con- 
centration of amorphous aggregate and the absence of 
amyloid formation and monomer uptake for samples 
lacking amorphous aggregate, all argue that an amorphous 
aggregate initiates amyloidogenesis. We suggest that a small 
fraction of the peptides on the surface of an amorphous 
aggregate possess the proper conformation to initiate fibril 
growth. Given the high P-sheet content of typical fibrils, 
these fibril-initiation peptides are most likely to be in an 
extended P-strand conformation. Monomeric peptides from 
solution align and attach through hydrogen bonds to these 
initiating peptides. This process is repeated, resulting in an 
extended p sheet and the formation of fibrils. 
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Other hypotheses regarding the process of amyloidogenesis 
have been presented. Lansbury and colleagues [Z&34] 
have suggested that amyloid formation is analogous to 
crystal growth. Using light scattering measurements as their 
principal technique for rnonitoring amyloidogenesis, they 
found that supersaturated solutions exhibit a lag period 
before fibril is detected and, further, that the lag period can 
be eliminated if the sample is seeded with mature fibrils. 
They therefore proposed that one-dimensional crys- 
tallization, similar to the polymerization of actin and other 
types of protein assembly, underlies the development of 
amyloid. Although one-dimensional crystallization success- 
fully explains their light lscattering data, it has been noted 
that accumulated PrPsc in diseased animals usually lacks 
the long range order that characterizes fibrils [35]. In addi- 
tion, Wille &al: [36] used fluorinated solvents to examine 
the importance of secondary structure in prion infectivity. 
By examining a proteolytic fragment of PrP [PrP(27-30)] in 
a range of cosolvent mixtures they demonstrated a clear 
separation of prion infectivity from amyloid formation. 
Lomakin eta/. [23] have used quasielastic light scattering to 
probe the time-dependent growth of fibrils produced from 
a fragment of the amyloid P-protein (l-40). They found 
that a critical concentration of 1OO~~I peptide is required 
for fibrilogenesis. Above this critical concentration they 
detected the presence of 14nm diameter micelles and it is 
argued that these micelles nucleate fibril growth. In the 
light of this work it is worthwhile considering whether the 
amorphous aggregate observed for the PrP(113-120)-SSL 
peptide is actually peptide that is sequestered in a micellar 
form. Micelles are unilamellar structures, lo-20nm across 
[37] that should readily pass through the 0.22~m filters 
used here to separate amorphous aggregate from monomer 
peptide. We have found that filtered solutions do not form 
amyloid as detected by either ESR or EM, however. Thus, 
we conclude that the amorphous aggregate identified for 
the PrP(113-120)-SSL is a large aggregate and probably 
not a micellar structure. 
The intermediate role of the amorphous aggregate in pro- 
moting amyloidogenesis is a new hypothesis that may lead 
to a clearer understanding of the conversion of PrPC to 
PrPsC and the subsequent formation of amyloid under 
some conditions. In contrast to the fibrillogenic theories 
outlined above, the conversion of PrPC to PrPsC is thought 
to take place through specific contacts within individual 
PrPsc-PrPC complexes. The mechanism that stabilizes 
PrP in the scrapie form, thereby halting reversion back to 
PrP”, has yet to be identified, however. 
It has been noted that PrPsc often accumulates as amor- 
phous aggregates upon purification. In addition, recent 
work suggests that aggregates of PrPsC can bind PrP”, 
sequestering it in a proteinase-K-resistant form [38]. The 
findings presented here suggest that the surface of an 
amorphous aggregate may promote formation of amyloid 
in a PrP-derived peptide. It is well established that PrPsC 
is rich in p sheet [7.8,36] and recent work suggests that 
nonfibrillar protein aggregates such as inclusion bodies 
may contain high levels of p sheet (A.L. Fink, personal 
communication). Thus, fibril-forming peptides may bind 
to the surface of amorphous aggregates via contacts similar 
to those that link adjacent strands in protein p sheets. For 
the prion protein, accumulation of PrPsc as amorphous 
aggregates helps stabilize the putative P-sheet region of 
PrPsC without any need for the formation of amyloid. 
Conclusion 
We have demonstrated that a spin-labeled PrP-derived 
peptide forms amyloid. When dissolved in aqueous solu- 
tion, the amplitude of the ESR spectrum of the peptide is 
time-dependent, indicating the uptake of monomer 
peptide as amyloid is formed. Probing the details of 
monomer uptake along with parallel EN studies suggest 
that amorphous aggregate is responsible for initiating fibril 
formation. It is possible that amorphous aggregate of PrP 
plays an analogous role in the conversion of PrP(; to PrPSC. 
The ESR methods developed here should readily extend 
to other peptides and proteins that form amyloid. 
Significance 
The scrapie form of the prion protein is thought to be 
responsible for the transmission of prion diseases such 
as scrapie, bovine spongioform encephalopathy and 
Creutzfeldt-Jakob disease. Fragments of the prion 
protein can assemble into amyloid, but little is known 
about the kinetics and mechanism of amyloid formation. 
Here, we have used electron spin resonance and elec- 
tron microscopy to show that a spin-labeled prion- 
derived peptide forms amyloid. Peptide monomer levels 
decrease as amyloid forms, and our results suggest that 
the formation of an amorphous peptide aggregate that is 
devoid of fibrils is required for fibril formation, and that 
the aggregate also releases peptide monomer into solu- 
tion. The techniques developed in this study may prove 
useful in investigations of other systems in which 
amyloid is formed. 
Materials and methods 
Peptide synthesis, purification, and spin labeling 
The peptides were synthesized by Fmoc solid-phase peptide synthesis 
on a Rainin PS3 peptide synthesizer with the carboxy-terminal alanine 
linked to p-benzyloxybenzyl alcohol (Wang) resin (Novabiochem, La 
Jolla, CA, USA). From residues four through seven, unreacted additions 
were capped with acetic anhydride (Fisher). All couplings were allowed 
to react for 100 min. The peptides were then cleaved with 90% trifluo- 
roacetic acid (TFA) / 5% triethylsilane / 5% anisole (Pierce, Rockford, IL, 
USA/Aldrich Chemical Co., Milwaukee, WI, USA/Aldrich). The trifluo- 
roacetic acid was distilled off under high vacuum, and the peptide pre- 
cipitated with f-butyl methyl ether (Aldrich). About 1 mg of crude peptide 
was dissolved in 50 ~1 trifluoroethanol (Aldrich) without aggregation. 
The volume of the sample was brought up to l.Oml with 0.1% TFA 
buffer pH 2.6 and immediately was injected into a HPLC fitted with an 
analytical Cl6 column (Alltech, Deerfield, IL, USA). Separation of the 
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unlabeled peptide was obtained with a binary water (pH 2.6) and ace- 
tonitrile (Fisher) gradient, where the acetonitrile proportion increased 
from 5% to 55% over 50min. Both solvents had 0.1% TFA as an ion- 
pairing reagent, and the total flow rate was 0.5mllmin. The collected 
fractions were then dried under vacuum and stored at -10°C. The 
peptide was reconstituted in 50 pl acetonitrile and reacted with a ten- 
fold excess of methanethiosulfonate spin label (MTSSL, Reanal, 
Hungary) for 2 h. The resulting spin-labeled peptide was again purified 
by reverse phase HPLC, and just prior to injection the sample was 
brought up to 1 .Oml with 5% acetonitrileI0.1 O/o aqueous TFA (pH 2.6) 
solution, The labeled peptide fraction was collected and dried under 
vacuum. The molecular weights of the unlabeled and labeled peptides 
were verified by fast atom bombardment mass spectrometry and agreed 
with the expected values to within 1 atomic mass unit. 
Centrifugal microfilters (Alltech, 0.22 km) were used to collect amyloid 
and amorphous aggregate. These samples were spun in a Fisher 
microcentrifuge for 1 min. The solid material retained on the filter was 
put in contact with fresh buffer solution by placing the filter in new 
buffer and vortexing for 20 s. 
Electron spin resonance 
The dry purified spin-labeled peptide sample was placed in a click top 
tube containing 30-50 pJ of buffer (0.1 M sodium acetate pH 5.5, here- 
after referred to as the standard buffer). The solution and peptide pellet 
were agitated with the plastic tip of the pipette for 10s. The solution 
was then vortexed for 1 OS and centrifuged for 5 s to break down the 
resultant foam. The solution was then drawn into a 100 t.d capillary tube 
and flame sealed at both ends. The ESR measurements were begun 
within 5 min following reconstitution in the buffer. 
Continuous wave ESR spectra of the spin-labeled peptides were 
acquired on a Bruker ESP 380 equipped with a dielectric resonator. 
The dielectric resonator was used due to its increased sensitivity, 
approximately a factor of five over the standard TE,,, resonator. Peptide 
concentrations down to 10 p.M were readily detected. Temperature 
control was maintained at 298K with a Bruker variable temperature unit. 
Concentrations were determined by double integration of the ESR 
spectra followed by quantitative comparison to a 1 .OmM 4-hydroxy- 
TEMPO (Aldrich) standard solution. The modulation frequency was 
100 kHz, and the amplitude was 0.66 G. Spectra were gathered over a 
100 G scan width. 
During kinetic trials, spectra were obtained every 7.5min for the first 
30 min, and every 15 min thereafter for 3 h. For eight samples, spectra 
were acquired every 24 h for up to two weeks. 
To determine the aggregate concentration, a background function rep- 
resenting the aggregate was constructed from the difference of two 
experimental spectra - one at low concentration (40 FM) containing no 
aggregate background and one at high concentration spectrum 
(610 wM) containing a large aggregate background. The broad singlet 
background gave an observed 33G (FVVHH) singlet. This signal was 
integrated and scaled to all the time=0 absorption spectra to derive 
initial aggregate concentrations. The fit was then subtracted from the 
original spectra, resulting in a monomer signal which was integrated 
(and compared to the tempo1 standard) to obtain the initial monomer 
concentrations. 
Transmission electron microscopy 
Sample grids were prepared by dipping a Gold-Seal glass slide into a 
1% Formvar solution. The films were floated off in nanopure water and 
picked up on copper 300 mesh grids. Aliquots (5~1) of -0.5mM 
peptide suspensions in the standard buffer were placed on the grids, 
allowed to sit for 45 s, and blotted on the periphery of the sample. The 
sample was negatively-stained with 2% (w/v) uranyl acetate for 45s 
and then again blotted. Samples were viewed with JEOL 100s and 
JEOL 1 OOB electron microscopes operating at 80 kV (JEOL USA Inc., 
Peabody, MA, USA). 
To obtain time course data, a copper grid was prepared as above imme- 
diately following dissolution in the buffer for the t=O data, and a new 
grid prepared every 30 min during the course of the amyloid reaction for 
4 h and again at 18 h. 
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